Plain-English translation of NCT07218432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a device called the TheraBionic P1, which uses special electromagnetic fields, can help improve treatment outcomes for women with early-stage breast cancer. The device is self-administered at home three times daily for at least two weeks before surgery. Researchers want to see if adding this treatment to surgery alone can help more cancer cells die.
Most women with early-stage hormone receptor positive breast cancer get surgery alone, but doctors are looking for ways to improve survival rates and reduce the chance of cancer returning. This trial explores whether this new electromagnetic field therapy might boost the body's ability to fight cancer cells.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would use the TheraBionic P1 device at home three times each day for at least two weeks leading up to your scheduled breast cancer surgery. The device uses electromagnetic fields and is self-administered, meaning you use it yourself. Your doctors will monitor you during this time, and tissue samples will be collected before and after surgery to see how well the treatment worked.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States